spacer
home > > winter 2003 > translating the pharma industry
PUBLICATIONS


Translating the Pharma Industry

The value of translations produced in the UK is thought to be worth more than 161 million according to some definitive research carried out last year. This figure may seem relatively low value compared with the market worth of the pharmaceutical sector as a whole, but considering the volume of actual translation jobs needed to produce such a global figure, translation is far from being an insignificant net contributor to UK plc.

Let's get the rest of the statistics out of the way. The translation profession is split into two segments; companies, of which there are around 1,500, and individual freelancers. It is estimated that there are around 8,000 to 9,000 freelance translators, although there are probably more since many individuals who offer translation or interpreting services rarely join one of the recognised professional bodies. The Association of Translation Companies is the only body regulating the company sector of the profession.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Geoffrey Bowden, General Secretary of the Association of Translation Companies

Geoffrey Bowden has been the General Secretary of the Association of Translation Companies for 23 years. In addition to his role with the ATC, he runs a successful PR consultancy, Nexus Structured Communications, specialising in the health sector. The client base of the consultancy includes household names in the pharmaceutical industry.

spacer
Geoffrey Bowden
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biognosys Announces Strategic Agreement with Siemens Healthineers

April 13th, 2021 SCHLIEREN, (Zurich, Switzerland) Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement